DCZ0415 |
カタログ番号GC39370 |
強力な TRIP13 阻害剤である DCZ0415 は、非相同末端結合修復を阻害し、NF-κB 活性を阻害します。 DCZ0415 は、in vitro、in vivo、および薬剤耐性骨髄腫患者由来の初代細胞で抗骨髄腫活性を誘導します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2242470-43-3
Sample solution is provided at 25 µL, 10mM.
DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1].
[1]. Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018.
Average Rating: 5
(Based on Reviews and 39 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *